NCT03093116 2026-04-03TRIDENT-1Turning Point Therapeutics, Inc.Phase 1/2 Recruiting500 enrolled 5 FDA
NCT03504397 2026-02-13SpotlightAstellas Pharma IncPhase 3 Active not recruiting565 enrolled 63 charts 3 FDA
NCT03653507 2026-02-06GLOWAstellas Pharma IncPhase 3 Active not recruiting507 enrolled 65 charts 3 FDA
NCT03329690 2022-03-18DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01]Daiichi SankyoPhase 2 Completed233 enrolled 26 charts 2 FDA
NCT01121393 2018-12-14BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)Boehringer IngelheimPhase 3 Completed364 enrolled 28 charts 2 FDA
NCT00949650 2018-04-06BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationBoehringer IngelheimPhase 3 Completed345 enrolled 23 charts 2 FDA